Skip to main content
. 2023 Jun 17;13:9841. doi: 10.1038/s41598-023-37007-1

Figure 1.

Figure 1

ERβ partially mediates 17α-E2 effects on mass and adiposity in obese female, but not male, mice. (A) Percent change in body mass over time [n = 9–10/group/timepoint], (B) Body mass at baseline (week 0; striped) and week 10 (solid) [n = 9–10/group/timepoint], (C) Percent change in fat mass over time [n = 9–10/group/timepoint], and (D) Fat mass at baseline (week 0; striped) and week 10 (solid) [n = 9–10/group/timepoint] in male WT and ERβKO mice. (E) Percent change in body mass over time [n = 7–9/group/timepoint], (F) Body mass at baseline (week 0; striped) and week 10 (solid) [n = 7–9/group/timepoint], (G) Percent change in fat mass over time [n = 7–9/group/timepoint], and (H) Fat mass at baseline (week 0; striped) and week 10 (solid) [n = 7–9/group/timepoint] in female WT and ERβKO mice. Age-matched, WT, LFD-fed mice were also evaluated as a normal-weight reference group and their corresponding means for both sexes are depicted as dashed yellow lines [n = 9/group/timepoint]. All data are presented as mean ± SEM and were analyzed within sex by two-way repeated measures ANOVA with Tukey post-hoc comparisons. For panels (A), (C), (E) and (G), * represents differences between WT HFD and WT HFD + 17α-E2, while # represents differences between ERβKO HFD and ERβKO HFD + 17α-E2. For panels (B), (D), (F), and (H), * represents differences within treatment group over time. *,#p < 0.05.